ESC Professional Premium Access

Relationship between endothelin-1, heart failure with reduced ejection fraction and dapagliflozin: findings from DAPA-HF

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Congress Presentation

About the speaker

Doctor Kieran Docherty

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)
2 presentations
0 follower

3 more presentations in this session

The real-world safety profile of SGLT2 inhibitors among adults 75 years or older: a retrospective, pharmacovigilance study

Speaker: Assistant Professor E. Maor (Tel Aviv, IL)

Thumbnail

Outcomes related to IGFBP-7 in patients with heart failure and reduced ejection fraction and effects of dapagliflozin: findings from DAPA-HF

Speaker: Doctor C. Adamson (Glasgow, GB)

Thumbnail

Efficacy of ertugliflozin on hospitalisation for heart failure across the distribution of pre-trial ejection fraction: post hoc analyses of the VERTIS CV trial

Speaker: Doctor A. Pandey (Dallas, US)

Thumbnail

Access the full session

SGLT2 inhibitors: pearls from recent trials and surveys

Speakers: Doctor K. Docherty, Assistant Professor E. Maor, Doctor C. Adamson, Doctor A. Pandey
Thumbnail

About the event

Image

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk